906673-24-3
Product Name:
Crisaborole
Formula:
C14H10BNO3
Synonyms:
4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile;5-(4-Cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole;5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole;AN2728
Inquiry
CHEMICAL AND PHYSICAL PROPERTIES
| Solubility | Insoluble |
|---|
SAFETY INFORMATION
| Signal word | Danger |
|---|---|
| Pictogram(s) |
 Skull and Crossbones Acute Toxicity GHS06 |
| GHS Hazard Statements |
H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
| Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P311:Call a POISON CENTER or doctor/physician. P301+P310:IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
COMPUTED DESCRIPTORS
| Molecular Weight | 251.05 g/mol |
|---|---|
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 251.0753733 g/mol |
| Monoisotopic Mass | 251.0753733 g/mol |
| Topological Polar Surface Area | 62.5 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 361 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Crisaborole is a non-steroidal anti-inflammatory drug that belongs to the benzoxaborole class. Specifically, it is a 5-hydroxy-1,3-dihydro-2,1-benzoxaborole with a 4-cyanophenyl group replacing the phenolic hydrogen. Functioning as a phosphodiesterase 4 (PDE4) inhibitor, crisaborole is utilized in the treatment of mild to moderate atopic dermatitis in both children and adults. Its role includes acting as an antipsoriatic agent and an inhibitor of phosphodiesterase IV.